Login to Your Account

Clinic Roundup

Friday, April 20, 2012

• Idenix Pharmaceuticals Inc., of Cambridge, Mass., reported data from a Phase I trial of IDX719, an NS5A inhibitor to treat hepatitis C virus (HCV) infection, demonstrating potent pan-genotypic antiviral activity with single doses. The study, initiated in January, evaluated the safety, pharmacokinetics and food effect of IDX719 in 40 healthy volunteers at single doses ranging from 5 mg to 100 mg. All doses were well tolerated, and pharmacokinetic data supported once-daily dosing in future studies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription